



Fang Wei & Chih-Ming Ho
Received: 12 December 2008 /Revised: 28 January 2009 /Accepted: 4 February 2009 /Published online: 24 February 2009
# The Author(s) 2009. This article is published with open access at Springerlink.com
Abstract We have developed an aptamer-based electro-
chemical sensor for detection of Botulinum neurotoxin,
where steric hindrance is applied to achieve specific signal
amplification via conformational change of the aptamer.
The incubation time and potassium concentration of the
reaction buffer were found to be key parameters affecting
the sensitivity of detection of the recognition of Botulinum
neurotoxin by the aptamer. Under optimized experimental
conditions, a high signal-to-noise ratio was obtained within
24 h with a limit of detection (LOD) of 40 pg/ml by two
standard deviation cutoffs above the noise level.
Keywords Aptamer . Botulinum neurotoxin . Biosafety .
Electrochemical biosensors . Steric hindrance . Conducting
polymer . Bioanalytical methods . Bioassays . Biosensors
Introduction
Botulinum neurotoxin (BoNT) is among the most toxic
substances known [1, 2]. Modeling studies shows 4 g per
gallon of BoNT in milk could cause rapid distribution more
than 400,000 causalities within days [3]. Therefore, rapid
and sensitive detection of BoNT are highly desirable for
addressing biosafety concerns. Among the seven defined
serotypes of BoNT (A to G), type A is the most frequent
cause of cases of human botulism [4]. Conventional methods
for detection of BoNT are primarily immunoassay-based and
have a sensitivity of 2–60 pg/ml [5, 6]. However, immuno-
assay of BoNT requires time-consuming and labor-intensive
process of screening highly specific human monoclonal
antibodies [5, 7]. In contrast, aptamers are fragments of
oligonucleotides which can bind specifically to target
proteins in the presence of appropriate conformational
change [8–10] and have the advantages of simpler screening
methods, higher stability than antibodies and reusability.
Recently, an efficient single micro-bead SELEX approach
has been developed to generate high-affinity single-stranded
DNA (ssDNA) aptamers against aldehyde-inactivated Botu-
linum neurotoxin type A (BoNT/A) [11]. The individual
dissociation constants (Kds) range from 3 nM to 50 nM for
different aptamer designs.
Here, we propose a strategy that combines an electro-
chemical method [12–15] with enzymatic amplification and
an aptamer probe that undergoes target-induced conforma-
tional change for the detection of BoNT/A toxoid (BoNT/A).
The electrochemical sensor has a streptavidin-dendrimer-
interfaced polypyrrole substrate to maintain the activity of
the aptamer and BoNT/A. The aptamer is dual-labeled with
a reporting tag (fluorescein) and an anchoring tag (biotin).
In the signal amplification process, an anti-fluorescein
antibody conjugated to horseradish peroxidase (HRP) is
introduced to bind to the fluorescein label on the aptamer.
After antibody binding 3, 3′, 5, 5′ tetramethylbenzidine
(TMB/H2O2) is added for the signal readout under
−200 mV potential. TMB acts as a mediator and is reduced
at −200 mV; the reduced TMB reduces the oxidized form
of HRP. HRP then reduces H2O2 to 2H2O and the HRP is
oxidized. This signal amplification process only occurs
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under conditions that permit HRP binding to the aptamer
on the surface. In the absence of BoNT/A binding, the
aptamer remains in the closed state and steric hindrance
[16, 17] from the sensor surface inhibits signal amplifica-
tion by preventing anti-fluorescein-HRP from accessing
the reporting tag fluorescein. After binding to BoNT/A, the
aptamer conformation opens up and permits access of the
HRP reporter, generating an electrochemical current signal.
Therefore, only the specific target BoNT/A can generate an
amplified current.
Materials and methods
Aptamer and BoNT/A toxoid
HPLC-purified aptamer oligonucleotides, biotin-labeled on
the 5′ end and fluorescein-labeled on the 3′ end, were
custom-synthesized (Operon Inc., Alabama, USA). Biotin
bound to surface streptavidin served as an anchor to the
electrode and the fluorescein label allowed for binding of
anti-fluorescein-HRP to amplify the electrochemical current
signal.
The 76-bp aptamer sequence for BoNT/A detection [11]
was 5′-ATACCAGCTTATTCAATT GAC ATG ACT GGG
ATT TTT GGC GAA ATC GAA GGA AGC GGA
GAGATAGTAAGTGCAATCT-3′.
Secondary structure and G-quadruplex searches were
done using Mfold [18, 19] and QGRS Mapper [20]. Two
possible G-quadruplex sequences were identified in the
BoNT/A aptamer, one beginning at position 28 with a
length of 29 bp and the other beginning at position 29 with
a length of 28 bp. Possible folding positions are underlined





BoNT/A toxoid (toxin inactivated by formaldehyde
treatment) with a molecular weight of 150 kDa was
purchased from Metabiologics, Inc (Madison, WI).
Surface fabrication of streptavidin-polypyrrole electrodes
The electrode surface consisted of a conducting layer of
streptavidin-coated polypyrrole (PPy) polymerized on gold
thin film. Streptavidin was introduced into the PPy matrix
by copolymerization of a streptavidin-modified DNA
dendrimer (Genisphere, USA, diameter 70–90 nm) and
pyrrole (Sigma, USA). The streptavidin-modified DNA
dendrimer was composed of short oligonucleotides and
could be easily incorporated into the PPy matrix due to the
negative charge of the dendrimer. Each dendrimer was
labeled with two to four streptavidin molecules.
For electropolymerization, the streptavidin-labeled den-
drimer was diluted with pyrrole in 1× PBS (pH 7.5,
Invitrogen, USA) at a ratio of 1:200 (v/v) for a final
concentration of 10 mM pyrrole. The electrodes were
covered with the mixture of dendrimer and pyrrole prior
electropolymerization. To avoid exposure of the dendrimer
to a strong electrical field and to form a smooth polymer
surface, square-wave electrical field was applied for
electropolymerization [21]. Each square-wave consisted of
9 s at a potential of +350 mVand 1 s at +950 mV. A total of
20 cycles of square-waves was applied and the entire
process lasted for 200 s. After polymerization, the electrode
was rinsed with ultra pure water (18.3 MΩcm) and dried
under a stream of pure N2. The polymer film was 51.5±
3.0 nm thick, as measured by a profilemeter (Dektak 6
Surface Profile Measuring System, Veeco). The surface
concentration of streptavidin-modified dendrimer was 0.30±
0.05 pmol/cm2, as measured with a scanning electron
microscope (Hitachi S4700 SEM, Japan).
Electrochemical detection
The electrochemical sensor consisted of a 16-unit gold
array. Each unit was comprised of three electrodes,
including the working electrode (WE), counter electrode
(CE), and reference electrode (RE) [17, 22]. The reference
electrode was determined to be +218 mV vs. SCE by
measuring cyclic voltammetric curves of 0.1 mM [Fe
(CN)6]
3−/4−. All electric potentials described in this report
are in reference to the gold reference electrode (+218 mV
vs. SCE) [17].
Two protocols were tested for aptamer-based BoNT/A
toxoid detection. One protocol was based on surface
recognition and the other was based on recognition in bulk
solution, followed by transfer onto the surface. For surface
recognition, 100 nM (50 μl) aptamer, dual-labeled with
biotin and fluorescein, in 1× Tris–HCl was first loaded onto
the electrode for conjugation to the streptavidin dendrimer;
the chip was washed and dried after 5 min of incubation.
Different concentrations of BoNT/A toxoid in volumes of
50 μl were then loaded onto the aptamer-coated surface. In
the second protocol, mixtures of BoNT/A toxoid at different
concentrations and 100 nM aptamer (50 μl total) were first
incubated for different periods of time and then transferred
onto the electrodes. To optimize the binding efficiency, the
effects of incubation times ranging from 1 h to 24 h were
investigated. In both protocols, the recognition buffer was
1× Tris–HCl containing 15 mM KCl, 140 mM NaCl, 1 mM
MgCl2, and 1 mM CaCl2. Since the efficiency of aptamer
binding to BoNT/A is correlated with metal cation
concentration [23, 24], buffers with different concentrations
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of KCl were also investigated. In both protocols, the
electrical field was applied to achieve effective binding
and correct folding of the aptamer [17, 25] with 20 cycles
of 9 s at−300 mV and 1 s at +200 mV, followed by washing
and drying. To generate amplification of signal specific for
BoNT/A, HRP conjugated to anti-fluorescein antibody
(Roche, USA) in casein/PBS buffer (50 μl; Pierce, USA)
was incubated with the electrodes for 5 min followed by
washing and drying of the chip. Finally, amperometric
measurements were carried out in the presence of 3, 3′, 5, 5′
tetramethylbenzidine (TMB/H2O2, Neogen Corp., Lexing-
ton, Kentucky, USA) low-activity substrate at −200 mV. In
our experiments, the electrochemical signal was the current
generated by the redox cycles between TMB, the HRP
reporter enzyme, and H2O2. All experiments were per-
formed at room temperature (Fig. 1).
Results
In-solution or surface-associated folding
of the BoNT/A aptamer
Detection of BoNT is based on the signal generated by the
conformational change of the aptamer. Correct folding of
the aptamer allows high-affinity binding between the
aptamer and BoNT/A toxoid; misfolding and non-folding
result in low signal-to-noise ratios (SNRs) [26]. In addition,
the specific signal amplification is strongly dependent on
the conformation of the aptamer before and after binding to
BoNT/A. Strong signal is generated by completely unfolded
aptamer binding to target BoNT/A and low noise occurs in
the presence of fully folded aptamer in the absence of target.
Therefore, understanding how to obtain correct folding of
aptamer is key to the detection process.
Specificity of BoNT/A aptamer binding was first
investigated by comparing the signal obtained with differ-
ent target proteins. Four non-target proteins were selected
as controls: 1% BSA, 0.1% casein, 100 ng/ml IL-8, and
100 ng/ml IL-1b and BoNT/A was assayed at a concentra-
tion of 100 ng/ml. BoNT/A aptamer alone was included as
a control. Figure 2 shows that the strongest signal was
generated by BoNT/A aptamer binding to BoNT/A. This
observation supports the assumption that the aptamer
maintains a closed conformation in the presence of
nonspecific target proteins and unfolds in the presence of
the complementary target. It also indicates the high
specificity of aptamer binding to BoNT/A toxoid.
Aptamer-based detection of BoNT/A can occur either on
the surface or in solution. In both processes, three factors
Fig. 1 Aptamer-based electrochemical detection of BoNT/A toxoid
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affect the final readout: the efficiency of aptamer-BoNT/A
binding, the efficiency of folding of the aptamer itself, and
the efficiency of immobilization of the aptamer on the
surface. In the surface recognition process, both the binding
of the aptamer to BoNT/A and self-folding of the aptamer
occur on the surface; the immobilization efficiency relates
only to the aptamer itself. In the in-solution recognition
process, both the binding of the aptamer to BoNT/A and
self-folding of the aptamer occur in solution. In contrast to
the surface recognition process, in-solution immobilization
efficiency relates to the aptamer-BoNT/A complex. Figure 3
shows amperometric detection data for these two types of
assay.
Figure 3 shows that the signal generated by recognition in
solution is approximately 900 nA higher than that generated
by recognition on the surface. The SNR is 6.8 for in-solution
recognition and 1.3 for the surface recognition. Background
levels are low in both processes (observed differences in
background may be the result of the different buffers used in
the immobilization and recognition processes). With the low
surface concentration of streptavidin (0.30±0.05 pmol/cm2),
crowding effect is not the critical problem for aptamer
surface binding. Since the concentrations of aptamer and
BoNT/A toxoid are identical in the two processes, the only
difference is the medium in which recognition takes place.
As discussed earlier, the SNR depends on the correct
folding of the aptamer. Therefore, the aptamer in solution
has higher binding and self-folding efficiency than the
aptamer immobilized on the surface. One possible expla-
nation for this phenomenon is that the aptamer in solution
can fold freely and has a greater chance of interacting with
target BoNT/A toxoid in three dimensions, resulting in a
higher possibility of correctly folding and docking with
target. However, folding of the aptamer on the surface of
the electrode may be constrained by chemical or physical
interactions between the aptamer and the surface; docking
with the target toxoid may be similarly restricted. Based on
the assumption that attachment of the aptamer to the surface
hinders the recognition of aptamer and target toxoid in this
manner, the remaining experiments were carried out using
recognition in solution.
Folding time and potassium concentration in aptamer-based
BoNT/A detection
Four different incubation times were investigated for
aptamer folding in in-solution recognition.
Amperometric data in Table 1 show that 1 h of
incubation results in poor recognition and an SNR of only
1.5. Both the sample and blank control had a current in the
range −200 to −400 nA. As the incubation time increased,
the signal for sample toxoid binding increased. After 24 h
of incubation, the current of BoNT/A reached −1986 nA,
which is 5.3 times higher than that seen for the 1-
h incubation. Meanwhile, as the sample signal increased
between 1 h and 24 h of incubation, the background signal
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Fig. 3 Aptamer-based detection by recognition on the surface and in
solution in the presence of 100 ng/ml BoNT/A toxoid
Table 1 Amperometric detection of BoNT/A toxoid following
different incubation times
Incubation time (hours) Isample
a/nA Iblank
b/nA SNR
1 −376±64 −256±26 1.5
3 −1142±197 −168±5 6.8
5 −1204±100 −100±2 12.0
24 −1986±42 −52±6 38.2
a Isample is the current measured at a BoNT/A toxoid concentration of
100 ng/ml
b Iblank is the current measured in the absence of BoNT/A toxoid















Fig. 2 Specificity of aptamer binding to BoNT/A toxoid. BoNT/A
aptamer was incubated with 100 ng/ml BoNT/A toxoid, 1% BSA,
0.1% Casein, 100 ng/ml IL-8, 100 ng/ml IL-1b, or PBS alone (blank)
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decreased from −256 nA to −52 nA and, following 24 h of
incubation, the SNR was 38. In the remainder of the
experiments, an incubation period of 24 h was used.
Another important parameter for aptamer folding and
binding to BoNT/A is the concentration of metal ions in the
solution [27–30]. Metal cations have been observed to
either stabilize or induce conformational change in
aptamers [31]. Metal cations also play an important role
in BoNT folding [32]. Among the alkali and earth alkali
metals commonly observed in biological systems, the
potassium ion has a diameter that fits well in the cavities
between guanine tetrads and potassium ion concentration
is highly correlated with the folding and docking of
aptamers [23]. Therefore, four reaction buffers containing
different concentrations of potassium ion were investigated
(Fig. 4). The correlation between potassium ion concentra-
tion and signal intensity was not simply linear. An optimal
potassium ion concentration of 15 mM was associated with
the highest signal and lowest background. Concentrations
of 0, 75, and 150 mM were associated with low signal and
high background.
The concentration profile for BoNT/A-aptamer binding
was obtained under the optimized assay conditions of
15 mM KCl and 24 h of incubation in solution (Fig. 5).
With the criterion of cutoff at two standard deviations
(SDV), the dynamic range extended from 100 ng/ml to
40 pg/ml and the limit of detection (LOD) was 40 pg/ml.
The optimized LOD of the aptamer-based electrochemical
sensor is comparable to that of the conventional immuno-
assay for BoNT detection (LOD 2–60 pg/ml) [6]. The
concentration profile with surface recognition was also
listed for comparison with the LOD of 2,560 pg/ml. The
surface recognition process between BoNT/A and BoNT/A
aptamer on surface shows a Langmuir model with the
binding constant K=2.0±0.5×10−6 (pg/ml)−1 (3.0±0.8×
109 M−1). This binding constant is relatively lower than the
1/Kds (3.3×10
8 M−1) from Tok’s work [11], which was
done on microbeads in solution. The lower K of BoNT/A
provides the supporting evidence that the binding efficiency
on flat gold surface is lower than that in solution. In addition,
the signal is not saturated with concentration below 150 ng/
ml BoNT/A. Therefore, the crowding effect is not the
major reason for the low SNR from surface recognition
process. The primary advantage of the aptamer-based
approach is that it precludes the necessity of generating a
specific monoclonal antibody and much shorter and
simpler procedure compared with immunoassay.
Discussion
Here, we report an aptamer-based BoNT/A detection
system that displays specific signal amplification and a
high SNR and is based on conformational change in the
aptamer induced by steric hindrance. This steric hindrance
is caused by either the opened or closed conformation of
the aptamer [17, 33]. When the aptamer binds to target
BoNT/A toxoid it is in its open state and signal increases. If
the target is not bound, the aptamer remains in its closed
conformation, resulting in low signal. Unlike a traditional
hairpin probe, which is designed with an inner stem region
so it can be triggered to open or close, this specific BoNT/A
aptamer does not contain such a “switch” in the sequence.
However, this aptamer has a relatively long sequence of
76 bp and two interior G-quadruplexes. Therefore, the
aptamer will be in a tightly coiled, or closed, state in the
absence of BoNT; after binding to BoNT conformational
change occurs. Most aptamer–protein binding events
consist of multi-point docking or surface–surface interac-
tions, rather than simple point–point docking. This complex









Fig. 4 Concentration profile for aptamer-based detection in the
presence of 100 ng/ml BoNT/A toxoid after 24 h of incubation in
buffer containing 0, 15, 75, or 150 mM KCl












Fig. 5 Concentration profile for aptamer-based detection of BoNT/A
toxoid after 24 h of incubation in solution and on surface with buffer
containing 15 mM KCl. Linear regression constant for recognition in
solution is R2=0.99, and for recognition on surface the results is R2=
0.94. The LOD is 40 pg/ml for recognition in solution and 2,560 pg/
ml for recognition on surface, with criteria of two standard deviations
above the blank control
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docking process results in the open conformation of the
BoNT/A aptamer.
In our optimization of incubation time, we observed that
short incubation times resulted in very low SNRs, while
longer incubation times resulted in high SNRs. One
possible explanation for this observation is based on the
reaction energy. A high energy barrier would exist and
several misfoldings would occur during the reaction
process, resulting in different quasi-stable intermediates.
Although the appropriate configuration is the most stable
one and has the lowest Gibbs free energy, trapping in the
quasi-stable intermediates can occur. In our investigation,
short durations of folding (less than 3 h of incubation)
generated an SNR of only 1.5, while longer-duration
(greater than 5 h) incubations generated SNRs of 12 or
greater (SNR of 38 after 24 h of incubation). This data
provides evidence supporting the existence of quasi-stable,
misfolded conformational intermediates prior to achieve-
ment of the final stable conformation.
To drive the reaction toward the thermodynamically stable
product, an important factor for correct folding is the ion
composition of the reaction buffer. Our data show that the
affinity of the aptamer for BoNT/A is dependent on the
potassium ion composition of the buffer, with a concentration
of 15 mM KCl generating the highest SNR. With the
potassium concentration optimized, the aptamer binds to
BoNT/A with high affinity and the LOD of the sensor is
40 pg/mL (400 fM). Other metal ions in addition to K+ should
also affect the folding of aptamer, including Ca2+, Mg2+, Na+.
Meanwhile, the folding process is also influenced by more
than a single type of ion and future work will investigate
optimized concentrations of combinations of multiple types of
ions, such as sodium, potassium, magnesium, and calcium.
Conclusion
Steric hindrance resulting from the structure of the aptamer
introduces specific and high signal after the aptamer binds
to BoNT/A toxoid. The binding affinity of the aptamer for
BoNT/A toxoid depends on correct folding of the aptamer.
Optimized incubation time and potassium ion concentration
results in a high signal-to-noise ratio. The LOD is 40 pg/ml
under optimized conditions within 24 h, which is much
shorter than the current record, 4 days.
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